An evaluation of the pharmacokinetics of donepezil HCl in patients with impaired hepatic function

British Journal of Clinical Pharmacology, Supplement

Volumn 46, Issue 1, 1998, Pages 51-55

  Tiseo, P J ^a   Vargas, R ^b   Perdomo, C A ^a   Friedhoff, L T ^a  

^a EISAI INC   (United States)

^b New Orleans Center for Clinical Research   (United States)

Author keywords

Alzheimer's disease; Donepezil; Hepatic impairment

Indexed keywords

DONEPEZIL;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG TOLERABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIVER CIRRHOSIS; LIVER DISEASE; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; ULTRAVIOLET SPECTROSCOPY;

EID: 0032420656     PISSN: 02643774     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1998.0460s1051.x     Document Type: Article

References (17)

1. Yamanishi Y, Ogura H, Kosasa T, Araki S, Sawa Y, Yamatsu K. Inhibitory action of E2020, a novel acetylcholinesterase inhibitor, on cholinesterase: comparison with other inhibitors. In Basic, Clinical, and Therapeutic Aspects of Alzheimer's and Parkinson's Diseases, Volume 2, eds Nagatsu T, Yoshida M, Fisher A. New York: Plenum Press, 1990: 409-413.
2. Rogers SL, Yamanishi Y, Yamatsu K. E2020 - the pharmacology of a piperidine cholinesterase inhibitor. In Cholinergic Basis for Alzheimer Therapy, eds Decker R, Giacobini E. Boston: Birkhäuser, 1991: 314-320.
3. Sugimoto H, Iimura Y, Yamanishi Y, Yamatsu K. Synthesis and antiacetylcholinesterase activity of 1-benzyl-4-[(5,6-dimethoxy-1-indanon-2-yl)methyl]piperidine hydrochloride (E2020) and related compounds. Bioorg Med Chem Lelt 1992; 2: 871-876.
4. 14C). J Label Compounds Radiopharm 1989; XXVII: 835-839.
5. Sherman K. Pharmacodynamics of oral E2020 and tacrinc in humans: novel approaches. In Cholinergic Basis for Alzheimer Therapy, eds Becker R, Giacobini E. Boston: Birkhäuser, 1991; 321-328.
6. Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicenter, randomized, double-blind, placebo-controlled trial. Dementia 1996; 7: 293-303.
7. Rogers SL, Doody RS, Mohs R, Friedhoff LT. E2020 produces both clinical global and cognitive test improvement in patients with mild to moderately severe Alzheimer's disease (AD): results of a 30-week Phase III trial. Neurology 1996; 46: A217 (S14.001).
8. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT, the Donepezil Study Group. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998; 50: 136-145.
9. Rogers SL, Doody RS, Mohs R, Friedhoff LT, the Donepezil Study Group. Donepezil improves cognition and global function in Alzheimer's disease: a 15-week, double-blind, placebo-controlled study. Arch Intern Med 1998; 158: 1021-1031.
10. Mihara M, Ohnishi A, Tomono Y et al. Pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy male volunteers. Int J Clin Pharmacol Ther Toxicol 1993; 31: 223-229.
11. Ohnishi A, Mihara M, Kamakura H et al. Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy young and elderly subjects. J Clin Pharmacol 1993; 33: 1086-1091.
12. Lee JW, Rogers SL, Friedhoff LT, Stiles MR, Cooper NM. Validation and application of an HPLC method for the determination of 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl] methyl piperidine hydrochloride (E2020) in human plasma. Pharm Res 1992; 9: S350.
13. Rogers SL, Perdomo C, Friedhoff LT. Clinical benefits are maintained during long-term treatment of Alzheimer's disease with the acetylcholinesterase inhibitor, E2020. Eur Neuropsychopharmacol 1995; 5: 386 (P-8-21).
14. Rogers SL, Friedhoff LT. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study. Eur Neuropsychopharmacol 1998; 8: 67-75.
15. Wagstaff AJ, McTavish D. Tacrine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer's disease. Drugs Aging 1994; 4: 510-540.
16. Crimson ML. Tacrine: first drug approved for Alzheimer's disease. Ann Pharmacother 1994; 28: 744-751.
17. Watkins PB, Zimmerman HJ, Knapp MJ et al. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994; 271: 992-998.